Marion McCourt - 02 Sep 2026 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Reporting relationship: EVP Commercial
Issuer ticker: REGN
Reported as of: 02 Sep 2026
Net transaction value: -$2,002,458
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:50:59 UTC
Prior SEC filing: 11 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Marion McCourt

Key filing fact

Marion McCourt filed Form 4 for REGENERON PHARMACEUTICALS, INC. (REGN) on 03 Sep 2026.

Key facts

This page summarizes Marion McCourt's Form 4 filing for REGENERON PHARMACEUTICALS, INC. (REGN).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:50.

Change

Previous filing in this sequence was filed on 11 Dec 2025.
Current net transaction value: -$2,002,458.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001663758 Primary reporting owner

McCourt Marion

Relationship: EVP Commercial
Address: 777 OLD SAW MILL RIVER ROAD, TARRYTOWN
Signature: /s/ Marion McCourt
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

REGN transaction

Common Stock

Sale

Transaction value: $1,032,750
Shares: -1,215
Change %: -8.5%
Price: $850.00
Shares after: 13,134
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1

REGN transaction

Common Stock

Sale

Transaction value: $969,708
Shares: -1,131
Change %: -8.6%
Price: $857.39
Shares after: 12,003
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1

REGN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 219
Date: 02 Sep 2026
Ownership: By 401(k) Plan

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 17, 2026.